Disruption of the Fanconi Anemia/BRCA Pathway in Sporadic Cancer

Overview

Journal Cancer Lett

Specialty Oncology

Date 2005 Oct 26

PMID 16246487

Citations 28

Authors

Alex Lyakhovich

Jordi Surralles

Affiliations

Soon will be listed here.

Abstract

An increasing number of studies provide evidences linking disruption of Fanconi anemia/BRCA cascade with sporadic cancers. Given that this pathway plays essential roles in response to the DNA interstrand cross-links, these cancers are expected to be chemosensitive to cross-link based therapy. In the present mini-review we expand the spectrum of possibilities for FA/BRCA disruption and review some works describing functional upstream and downstream events linking disruption of the FA/BRCA pathway to sporadic cancer. This may involve but not limited to epigenetic silencing of the FA-core complex or BRCA1/2, mutations of one or several FA-BRCA genes or modification of encoded products. All this may serve as a platform for occurrence, development and treatment of sporadic cancers and therefore deserves to be in the focus of new research directions.

Citing Articles

Genomic Analysis Made It Possible to Identify Gene-Driver Alterations Covering the Time Window between Diagnosis of Neuroblastoma 4S and the Progression to Stage 4.

Ognibene M, De Marco P, Parodi S, Meli M, Di Cataldo A, Zara F Int J Mol Sci. 2022; 23(12).

PMID: 35742955 PMC: 9224358. DOI: 10.3390/ijms23126513.

Genome Instability in Multiple Myeloma: Facts and Factors.

Aksenova A, Zhuk A, Lada A, Zotova I, Stepchenkova E, Kostroma I Cancers (Basel). 2021; 13(23).

PMID: 34885058 PMC: 8656811. DOI: 10.3390/cancers13235949.

The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.

Xing L, Mi W, Zhang Y, Tian S, Zhang Y, Qi R J Cell Mol Med. 2020; 24(17):9839-9852.

PMID: 32762026 PMC: 7520306. DOI: 10.1111/jcmm.15567.

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.

Wesolowski R, Stover D, Lustberg M, Shoben A, Zhao M, Mrozek E Oncologist. 2020; 25(8):e1158-e1169.

PMID: 32452601 PMC: 7418347. DOI: 10.1634/theoncologist.2020-0039.

Common Metabolic Pathways Implicated in Resistance to Chemotherapy Point to a Key Mitochondrial Role in Breast Cancer.

Abad E, Garcia-Mayea Y, Mir C, Sebastian D, Zorzano A, Potesil D Mol Cell Proteomics. 2018; 18(2):231-244.

PMID: 30373788 PMC: 6356073. DOI: 10.1074/mcp.RA118.001102.